Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury.
MouseEndotoxin/LPSC57BL/6Male48 h before galactosamine/lipopolysaccharide challenge
Model: Galactosamine/lipopolysaccharide-induced acute liver failure
DBTC/siRNA(Fas) reduced hepatic but not extrahepatic Fas expression, improved hepatic perfusion, reduced hepatocellular death and increased survival after galactosamine/lipopolysaccharide. TNF-alpha mRNA fell markedly while plasma IL-6 was unchanged, so protection from inflammation was only partial.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.